BMY

47.63

0.25% 0.12

시간 외 거래: 47.62 -0.01 -0.02%

브리스톨 마이어스 스퀴브 (BMY)

개요 뉴스 가격 이력 옵션 체인 Financials BMY 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$47.51

열려 있는:

$47.59

하루 거래량:

12.29M

Relative Volume:

0.87

시가총액:

$101.69B

수익:

$47.64B

순이익/손실:

$5.42B

주가수익비율:

17.84

EPS:

2.67

순현금흐름:

$13.09B

1주 성능:

+2.04%

1개월 성능:

-2.38%

6개월 성능:

-16.13%

1년 성능:

+17.75%

1일 변동 폭

$47.35

$48.22

1주일 범위

$46.16

$48.26

52주 변동 폭

$39.35

$63.33

브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile

명칭

Bristol Myers Squibb Co

부문

Healthcare (1166)

산업

Drug Manufacturers - General (19)

전화

(609) 252-4621

주소

ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY

직원

34,100

트위터

@BMSNEWS

다음 수익 날짜

2024-10-31

최신 SEC 제출 서류

BMY's Discussions on Twitter

BMY을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
BMY Bristol Myers Squibb Co	47.63	101.69B	47.64B	5.42B	13.09B	2.67
LLY Lilly Eli Co	779.28	724.64B	49.00B	11.11B	-1.27B	12.29
JNJ Johnson Johnson	155.56	376.43B	89.33B	21.81B	18.57B	8.99
NVO Novo Nordisk Adr	69.82	352.49B	43.59B	15.04B	10.74B	3.3766
ABBV Abbvie Inc	190.75	334.73B	57.37B	4.20B	15.39B	2.35
NVS Novartis Ag Adr	123.81	234.21B	53.22B	12.86B	14.85B	6.39

브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-04-22	개시	Cantor Fitzgerald	Neutral
2025-04-22	개시	Piper Sandler	Overweight
2024-12-16	업그레이드	Jefferies	Hold → Buy
2024-12-10	재개	BofA Securities	Neutral
2024-11-15	개시	Wolfe Research	Peer Perform
2024-11-13	업그레이드	Daiwa Securities	Neutral → Outperform
2024-11-12	업그레이드	Leerink Partners	Market Perform → Outperform
2024-10-25	다운그레이드	Citigroup	Buy → Neutral
2024-10-17	개시	Bernstein	Mkt Perform
2024-07-29	다운그레이드	Barclays	Overweight → Equal Weight
2024-03-11	다운그레이드	Societe Generale	Buy → Hold
2024-02-06	다운그레이드	Redburn Atlantic	Buy → Neutral
2024-01-03	다운그레이드	BofA Securities	Buy → Neutral
2023-11-15	다운그레이드	Cantor Fitzgerald	Overweight → Neutral
2023-11-09	개시	Deutsche Bank	Hold
2023-11-02	다운그레이드	Daiwa Securities	Outperform → Neutral
2023-10-27	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2023-10-27	업그레이드	HSBC Securities	Reduce → Hold
2023-10-27	다운그레이드	William Blair	Outperform → Mkt Perform
2023-10-20	재개	UBS	Neutral
2023-07-14	개시	HSBC Securities	Reduce
2023-07-10	개시	SVB Securities	Market Perform
2023-06-28	개시	Daiwa Securities	Outperform
2023-03-06	개시	Jefferies	Hold
2023-01-17	개시	Cantor Fitzgerald	Overweight
2022-11-18	개시	Credit Suisse	Neutral
2022-10-10	다운그레이드	Guggenheim	Buy → Neutral
2022-09-14	다운그레이드	Berenberg	Buy → Hold
2022-06-03	다운그레이드	Raymond James	Outperform → Mkt Perform
2022-04-06	재개	Morgan Stanley	Underweight
2021-12-17	개시	Goldman	Buy
2021-12-09	재개	Wells Fargo	Equal Weight
2021-11-19	개시	BMO Capital Markets	Outperform
2021-11-01	다운그레이드	Argus	Buy → Hold
2021-07-27	재개	Truist	Buy
2021-04-30	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-04-13	업그레이드	Truist	Hold → Buy
2020-11-16	업그레이드	Societe Generale	Hold → Buy
2020-11-10	재개	Bernstein	Mkt Perform
2020-11-06	다운그레이드	Gabelli & Co	Buy → Hold
2020-10-19	업그레이드	Guggenheim	Neutral → Buy
2020-09-29	개시	Berenberg	Buy
2020-07-28	개시	Raymond James	Outperform
2020-04-02	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2020-03-23	다운그레이드	Societe Generale	Buy → Hold
2020-02-27	개시	Barclays	Equal Weight
2020-01-06	재개	Citigroup	Buy
2019-12-13	업그레이드	Argus	Hold → Buy
2019-11-22	재개	Morgan Stanley	Equal-Weight
2019-10-17	재개	BofA/Merrill	Buy
2019-08-14	업그레이드	Atlantic Equities	Neutral → Overweight
2019-05-28	개시	Goldman	Buy
2019-05-20	다운그레이드	Argus	Buy → Hold
2019-05-03	업그레이드	Barclays	Equal Weight → Overweight
2019-05-03	재개	JP Morgan	Overweight
2019-01-15	업그레이드	Societe Generale	Sell → Buy
2018-10-22	다운그레이드	Citigroup	Buy → Neutral

모두보기

브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스

Jun 18, 2025

Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus

Jun 18, 2025

Bristol-Myers (NYSE:BMY) Squibb Dividend Update Reflects Steady Healthcare NYSE Composite - Kalkine Media

Jun 18, 2025

Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - Yahoo

Jun 18, 2025

BioNTech and Bristol Myers Squibb Collaborate on BNT327, a PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com

Jun 18, 2025

Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile

Jun 18, 2025

Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus

Jun 18, 2025

Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus

Jun 18, 2025

Jun 17, 2025

Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global

Jun 17, 2025

Bristol Myers Squibb declares quarterly dividend of $0.62 per share By Investing.com - Investing.com Nigeria

Jun 17, 2025

BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Therapy - geneonline.com

Jun 17, 2025

Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - MSN

Jun 17, 2025

Jun 16, 2025

Bristol Myers Squibb (BMY) Shares Cross 5% Yield Mark - Nasdaq

Jun 16, 2025

Myocardial Infarction Market Is Booming So Rapidly 2025-2032 - openPR.com

Jun 16, 2025

Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co - Yahoo Finance

Jun 16, 2025

Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial - MSN

Jun 16, 2025

Bristol Myers Squibb (BMY) Achieves Strong Results with Breyanzi in Lymphoma Study - GuruFocus

Jun 16, 2025

Bristol Myers: positive phase 2 data in lymphoma - MarketScreener

Jun 16, 2025

Bristol Myers (BMY) Reports Promising Results from Lymphoma Stud - GuruFocus

Jun 16, 2025

Schizophrenia Drugs Market Size, Share & Forecast 2025 | Major - openPR.com

Jun 16, 2025

Bristol-Myers Squibb (BMY) Stock Analysis: Healthcare Giant with a 14.77% Potential Upside - DirectorsTalk Interviews

Jun 16, 2025

Business development leadership team - Bristol Myers Squibb

Jun 16, 2025

BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com

Jun 16, 2025

Rockland Trust Co. Sells 20,035 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Jun 16, 2025

Jun 15, 2025

Jim Cramer on Bristol Myers: “We Need to See That Stock Back Up at $60” - Insider Monkey

Jun 15, 2025

Jun 14, 2025

BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment - geneonline.com

Jun 14, 2025

Bristol-Myers Squibb’s SWOT analysis: stock outlook amid Cobenfy growth and pipeline potential - Investing.com

Jun 14, 2025

Jun 13, 2025

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' - Endpoints News

Jun 13, 2025

Jun 12, 2025

Bristol Myers (BMY) Showcases Promising New Data on Targeted Pro - GuruFocus

Jun 12, 2025

Bristol-Myers Promotes Attorney To Lead Corporate Affairs - Law360

Jun 12, 2025

BioNTech and Bristol Myers Squibb Partner to Develop BNT327 Antibody Targeting PD-L1 and VEGF-A Pathways in Tumors - geneonline.com

Jun 12, 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu Compared with Placebo in Adults with Psoriatic Arthritis - marketscreener.com

Jun 12, 2025

Bristol-Myers stock holds steady as Cantor maintains neutral rating By Investing.com - Investing.com South Africa

Jun 12, 2025

BMY Reports Positive Data on Sotyktu From Arthritis Study - TradingView

Jun 12, 2025

Bristol Myers Squibb promotes Wendy Bartie to lead corporate affairs - PR Week UK

Jun 12, 2025

Bristol Myers: new data to be presented in hematology - marketscreener.com

Jun 12, 2025

Bristol-Myers stock holds steady as Cantor maintains neutral rating - Investing.com

Jun 12, 2025

Bristol Myers Squibb presents protein degradation data at EHA By Investing.com - Investing.com India

Jun 12, 2025

Bristol Myers Squibb presents protein degradation data at EHA - Investing.com

Jun 12, 2025

Bristol Myers Squibb Sets Q2 2025 Earnings Date: Key Financial Results Coming July 31 - Stock Titan

Jun 12, 2025

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - The Joplin Globe

Jun 12, 2025

Jun 11, 2025

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - MSN

Jun 11, 2025

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu - Yahoo Finance

Jun 11, 2025

Bristol Myers at Goldman Sachs Conference: Strategic Insights on Growth - Investing.com Australia

Jun 11, 2025

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive

Jun 11, 2025

Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025

Bristol Myers (BMY) Sees Promising Results for Sotyktu in Phase 3 Trial - GuruFocus

Jun 11, 2025

BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com

Jun 11, 2025

Bristol-Myers Squibb To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq

Jun 11, 2025